JP7745571B2 - 肺線維症を処置する方法 - Google Patents

肺線維症を処置する方法

Info

Publication number
JP7745571B2
JP7745571B2 JP2022572568A JP2022572568A JP7745571B2 JP 7745571 B2 JP7745571 B2 JP 7745571B2 JP 2022572568 A JP2022572568 A JP 2022572568A JP 2022572568 A JP2022572568 A JP 2022572568A JP 7745571 B2 JP7745571 B2 JP 7745571B2
Authority
JP
Japan
Prior art keywords
pulmonary fibrosis
formula
acid
compound
idiopathic pulmonary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022572568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527358A (ja
JP2023527358A5 (cg-RX-API-DMAC7.html
Inventor
クリス バーンズ,
ジョン ランバート,
マーク グレーム デブリン,
Original Assignee
アンプリア セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901743A external-priority patent/AU2020901743A0/en
Application filed by アンプリア セラピューティクス リミテッド filed Critical アンプリア セラピューティクス リミテッド
Publication of JP2023527358A publication Critical patent/JP2023527358A/ja
Publication of JP2023527358A5 publication Critical patent/JP2023527358A5/ja
Application granted granted Critical
Publication of JP7745571B2 publication Critical patent/JP7745571B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022572568A 2020-05-28 2021-05-17 肺線維症を処置する方法 Active JP7745571B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020901743A AU2020901743A0 (en) 2020-05-28 Methods of treating pulmonary fibrosis
AU2020901743 2020-05-28
PCT/AU2021/050457 WO2021237273A1 (en) 2020-05-28 2021-05-17 Methods of treating pulmonary fibrosis

Publications (3)

Publication Number Publication Date
JP2023527358A JP2023527358A (ja) 2023-06-28
JP2023527358A5 JP2023527358A5 (cg-RX-API-DMAC7.html) 2024-05-14
JP7745571B2 true JP7745571B2 (ja) 2025-09-29

Family

ID=78745664

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022572568A Active JP7745571B2 (ja) 2020-05-28 2021-05-17 肺線維症を処置する方法

Country Status (7)

Country Link
EP (1) EP4157278A4 (cg-RX-API-DMAC7.html)
JP (1) JP7745571B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230017843A (cg-RX-API-DMAC7.html)
CN (1) CN115867281A (cg-RX-API-DMAC7.html)
AU (1) AU2021279205B2 (cg-RX-API-DMAC7.html)
CA (1) CA3177652A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021237273A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020245902B2 (en) 2019-03-28 2025-01-02 Amplia Therapeutics Limited A salt and crystal form of a FAK inhibitor
WO2023139154A1 (en) * 2022-01-19 2023-07-27 Nordic Bioscience A/S A method for detecting covid-19 in a patient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2675794T3 (da) 2011-02-17 2019-05-06 Cancer Therapeutics Crc Pty Ltd Selektive fak-inhibitorer
WO2014027199A1 (en) * 2012-08-14 2014-02-20 Cancer Therapeutics Crc Pty Ltd Fak and flt3 inhibitors
AU2020245902B2 (en) * 2019-03-28 2025-01-02 Amplia Therapeutics Limited A salt and crystal form of a FAK inhibitor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Joana Carvalho,FDA Names AMP945, Potential IPF Treatment, an Orphan Drug,online,2020年05月20日,URL: https://pulmonaryfibrosisnews.com/news/fda-names-amp945-potential-idiopathic-pf-treatment-orphan-drug/
Peter M GEORGE et al.,"Pulmonary fibrosisand COVID-19: the potential role for antifibrotic therapy",The Lancet Respiratory Medicine,2020年05月15日,Vol. 8, No. 8,p.807-815,DOI: 10.1016/S2213-2600(20)30225-3

Also Published As

Publication number Publication date
JP2023527358A (ja) 2023-06-28
AU2021279205A1 (en) 2022-12-08
US20230190746A1 (en) 2023-06-22
CN115867281A (zh) 2023-03-28
CA3177652A1 (en) 2021-12-02
AU2021279205B2 (en) 2025-12-04
EP4157278A4 (en) 2024-07-03
KR20230017843A (ko) 2023-02-06
EP4157278A1 (en) 2023-04-05
NZ793855A (en) 2026-02-27
WO2021237273A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
US20220152057A1 (en) Methods and compositions for treating various disorders
AU2018357775B2 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
JP6827948B2 (ja) 呼吸器疾患の治療
EP3551187B1 (en) Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
HUP0204079A2 (hu) Szedatív hatástól mentes antihisztaminok és leukotrién hatást befolyásoló anyagok új kombinációja orrnyálkahártya-gyulladás, vagy kötőhártya-gyulladás kezelésére
US20100093754A1 (en) Pharmaceutical Compositions Comprising Flibanserin and a Further Agent in the Treatment of Sexual Disorders
JP2010514696A (ja) 心血管症状の低減
JP2013166761A (ja) 多発性硬化症を処置するためのs1p受容体モジュレーター
JP2009526829A (ja) 流涎症の治療のためのアルファ−2受容体アゴニスト(クロニジン)と抗ムスカリン剤(オキシブチニン)との組み合わせ
US20130079304A1 (en) Pharmaceutical Compositions for the Treatment of Fungal Infections
AU2021279205B2 (en) Methods of treating pulmonary fibrosis
JP2010533166A (ja) シロスタゾールを含むカルボスチリル誘導体の脂肪肝治療剤
US8648100B2 (en) Roflumilast for the treatment of pulmonary hypertension
FI4199922T3 (fi) (1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa
EA007952B1 (ru) Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии
JP6051315B2 (ja) 乾癬を処置するためのピドチモドの使用
JP2026510948A (ja) 慢性閉塞性肺疾患患者におけるエンテロウイルスの治療方法
JP2024534156A (ja) Nurr1アゴニストの、アルドステロンアンタゴニスト、インスリンモジュレーター及びスルホニル尿素のうちの少なくとも1つとの組合せ
RU2809024C2 (ru) Монтелукаст для лечения эрозивного остеоартрита кистей рук
CN119522109A (zh) 用于钙调磷酸酶抑制剂的间歇性给药的组合物
CN118252832A (zh) Vofopitant用于治疗硬皮病的用途
HK40054679A (en) Montelukast for the treatment of erosive hand osteoarthritis
HK40054679B (en) Montelukast for the treatment of erosive hand osteoarthritis
HK1221913B (en) Use of par-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions
JP2000290198A (ja) 鼻腔抵抗上昇等の抑制剤

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250527

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250821

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250916

R150 Certificate of patent or registration of utility model

Ref document number: 7745571

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150